Reuters: Regulatory News: CORRECTED-J&J's Zytiga to be reviewed faster by FDA for additional use

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

CORRECTED-J&J's Zytiga to be reviewed faster by FDA for additional use Aug 29th 2012, 14:14 Wed Aug 29, 2012 10:14am EDT Aug 29 (Reuters) - Johnson & Johnson said an application to gain approval for a new usage of its prostate cancer treatment Zytiga won a priority review status from U.S. health regulators, meaning that the drug would be reviewed faster than usual. The company is trying to get Zytiga approved to treat prostate cancer patients who have not undergone chemotherapy. The drug gained U.S. approval in 2011 to treat prostate cancer patients who have previously received chemotherapy. The priority review status, which is granted by the FDA to expedite the review of drugs to treat serious diseases and fill unmet medical needs, means that the drug would be reviewed in six months rather than the usual 10 to 12-months. Zytiga's worldwide sales rose about $32 million sequentially to $232 million in the second quarter. The company said it had submitted the application in June. (Reporting by Zeba Siddiqui in Bangalore; Editing by Akshay Lodaya)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions